TT-232 is a synthetic peptide derivative of somatostatin.1 It binds to somatostatin receptors in isolated rat synaptosomal membranes (IC50 = ~0.1 nM). TT-232 (30 and 60 µg/ml) inhibits the proliferation of P388 murine and HL-60 human leukemia cells.2 In vivo, TT-232 (3-12 µg/animal per day) reduces tumor volume in an HL-60 mouse xenograft model. It inhibits intradermal neutrophil accumulation and ear edema induced by capsaicin in rats.3 TT-232 (5-20 µg/kg, i.p.) inhibits mechano-nociceptive hyperalgesia in rats.
1.Simon, Á., KÉri, G., and Kardos, J.Comparison of the binding modes of TT-232 in somatostatin receptors type 1 and 4Theochem.816(1-3)73-76(2007) 2.Tejeda, M., Gaal, D., Csuka, O., et al.Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia modelsAnticancer Res.25(1A)325-330(2005) 3.PintÉr, E., Helyes, Z., NÉmeth, J., et al.Pharmacological characterisation of the somatostatin analogue TT-232: Effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesiaNaunyn Schmiedebergs Arch. Pharmacol.366(2)142-150(2002)